What is your preferred adjuvant systemic treatment for resected stage IV melanoma with a BRAF mutation?

I agree with @Dr. First Last and prefer single-agent anti-PD1 therapy for adjuvant setting as well, given better tolerance and preserved QoL for most patients. I use targeted therapy in contraindications to ICI therapy, or prior exposure to ICI, and now with resected NED setting.

Unless there is a contraindication to immunotherapy, I would recommend the standard of care single agent PD1 inhibitor. If there is a contraindication, BRAF inhibitors are the drugs of choice.